Ugo Salvadori1, Fabio Vittadello2, Ahmad Al-Khaffaf1, Armin Maier3, Paola C Cappelletto4, Massimo Daves1, Bernd Raffeiner3. 1. Department of Immunohaematology and Transfusion, Central Hospital of Bolzano, Bolzano, Italy. 2. Explora - Research and Statistical Analysis, Padova, Italy. 3. Rheumatology Unit, Department of Medicine, Central Hospital of Bolzano, Bolzano, Italy. 4. Hospital Pharmacy, Central Hospital of Bolzano, Bolzano, Italy.
Abstract
BACKGROUND: The aim of this study was to evaluate the efficacy and safety of ferric carboxymaltose in rheumatic patients with iron deficiency anaemia. MATERIALS AND METHODS: The study retrospectively evaluated a cohort of 34 patients with iron deficiency anaemia affected by inflammatory rheumatic diseases that are refractory or intolerant to oral iron therapy. They were treated with ferric carboxymaltose for a total of 56 cycles of treatment. The primary end point was to evaluate the increase of haemoglobin after ferric carboxymaltose treatment. The secondary end point was safety, including the occurrence of disease flare. RESULTS: Median age of the cohort was 60 years (range 31-91 years), with a male/female ratio of 4/30. Nine (26.5%) were affected by rheumatoid arthritis, 10 (29.4%) by spondyloarthritis, and 15 (44.1%) by other autoimmune connective tissue diseases. Median time from diagnosis was 7 years (IQR 2-12). At time of treatment (T0), median haemoglobin was 9.3 g/dL (IQR 8.2-10.3), transferrin saturation 6.2% (IQR 3.8-9.8), and ferritin 8.5 ng/mL (IQR 6.0-12.8). Median ferric carboxymaltose dose was 1,000 mg. At 6 weeks from T0, median haemoglobin was 12.3 g/dL (IQR 11.6-13.3), with a mean increase of 3.0 g/dL (p<0.01). Twelve (35.3%) patients needed re-treatment with ferric carboxymaltose for recurrence of iron deficiency anaemia. Four (4.3%) patients developed mild grade side effects. One suspected flare reaction has been observed. DISCUSSION: In patients affected by inflammatory rheumatic diseases, ferric carboxymaltose is safe and effective in correcting iron deficiency anaemia.
BACKGROUND: The aim of this study was to evaluate the efficacy and safety of ferric carboxymaltose in rheumaticpatients with iron deficiency anaemia. MATERIALS AND METHODS: The study retrospectively evaluated a cohort of 34 patients with iron deficiency anaemia affected by inflammatory rheumatic diseases that are refractory or intolerant to oral iron therapy. They were treated with ferric carboxymaltose for a total of 56 cycles of treatment. The primary end point was to evaluate the increase of haemoglobin after ferric carboxymaltose treatment. The secondary end point was safety, including the occurrence of disease flare. RESULTS: Median age of the cohort was 60 years (range 31-91 years), with a male/female ratio of 4/30. Nine (26.5%) were affected by rheumatoid arthritis, 10 (29.4%) by spondyloarthritis, and 15 (44.1%) by other autoimmune connective tissue diseases. Median time from diagnosis was 7 years (IQR 2-12). At time of treatment (T0), median haemoglobin was 9.3 g/dL (IQR 8.2-10.3), transferrin saturation 6.2% (IQR 3.8-9.8), and ferritin 8.5 ng/mL (IQR 6.0-12.8). Median ferric carboxymaltose dose was 1,000 mg. At 6 weeks from T0, median haemoglobin was 12.3 g/dL (IQR 11.6-13.3), with a mean increase of 3.0 g/dL (p<0.01). Twelve (35.3%) patients needed re-treatment with ferric carboxymaltose for recurrence of iron deficiency anaemia. Four (4.3%) patients developed mild grade side effects. One suspected flare reaction has been observed. DISCUSSION: In patients affected by inflammatory rheumatic diseases, ferric carboxymaltose is safe and effective in correcting iron deficiency anaemia.
Authors: Michael Auerbach; John Adamson; Andreas Bircher; Christian Breymann; Steven Fishbane; Anat Gafter-Gvili; Christoph Gasche; Jeffrey Gilreath; Giuliano Grazzini; David Henry; Giancarlo Liumbruno; Francesco Locatelli; Iain Macdougall; Manuel Munoz; David Rampton; George Rodgers; Aryeh Shander Journal: Haematologica Date: 2015-05 Impact factor: 9.941
Authors: Refael Segal; Yehuda Baumoehl; Ori Elkayam; David Levartovsky; Irena Litinsky; Daphna Paran; Irena Wigler; Beni Habot; Arthur Leibovitz; Ben Ami Sela; Dan Caspi Journal: Rheumatol Int Date: 2003-04-29 Impact factor: 2.631
Authors: Maria Domenica Cappellini; Josep Comin-Colet; Angel de Francisco; Axel Dignass; Wolfram Doehner; Carolyn S Lam; Iain C Macdougall; Gerhard Rogler; Clara Camaschella; Rezan Kadir; Nicholas J Kassebaum; Donat R Spahn; Ali T Taher; Khaled M Musallam Journal: Am J Hematol Date: 2017-07-07 Impact factor: 10.047